DK2976337T3 - 5-amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists - Google Patents

5-amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists Download PDF

Info

Publication number
DK2976337T3
DK2976337T3 DK13811624.9T DK13811624T DK2976337T3 DK 2976337 T3 DK2976337 T3 DK 2976337T3 DK 13811624 T DK13811624 T DK 13811624T DK 2976337 T3 DK2976337 T3 DK 2976337T3
Authority
DK
Denmark
Prior art keywords
methyl
quinoline
amino
carboxamide
piperidinyl
Prior art date
Application number
DK13811624.9T
Other languages
Danish (da)
English (en)
Inventor
Ramakrishna Nirogi
Anil Karbhari Shinde
Venkateswarlu Jasti
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Application granted granted Critical
Publication of DK2976337T3 publication Critical patent/DK2976337T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
DK13811624.9T 2013-03-20 2013-10-18 5-amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists DK2976337T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1199CH2013 IN2013CH01199A (OSRAM) 2013-03-20 2013-10-18
PCT/IN2013/000639 WO2014147636A1 (en) 2013-03-20 2013-10-18 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists

Publications (1)

Publication Number Publication Date
DK2976337T3 true DK2976337T3 (en) 2018-07-16

Family

ID=54325095

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13811624.9T DK2976337T3 (en) 2013-03-20 2013-10-18 5-amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists

Country Status (18)

Country Link
US (1) US9790211B2 (OSRAM)
EP (1) EP2976337B1 (OSRAM)
JP (1) JP6185650B2 (OSRAM)
KR (1) KR101815307B1 (OSRAM)
CN (1) CN105164119B (OSRAM)
AP (1) AP2015008742A0 (OSRAM)
AU (1) AU2013382944B2 (OSRAM)
BR (1) BR112015024060A2 (OSRAM)
CA (1) CA2907620C (OSRAM)
DK (1) DK2976337T3 (OSRAM)
EA (1) EA029365B1 (OSRAM)
ES (1) ES2674993T3 (OSRAM)
IN (1) IN2013CH01199A (OSRAM)
MX (1) MX364929B (OSRAM)
NZ (1) NZ712369A (OSRAM)
SG (1) SG11201507763RA (OSRAM)
WO (1) WO2014147636A1 (OSRAM)
ZA (1) ZA201506804B (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3265459T3 (pl) * 2015-02-13 2019-09-30 Suven Life Sciences Limited Związki amidowe jako agoniści receptora 5-HT4
CN109444301A (zh) * 2018-12-18 2019-03-08 江苏省中医院 一种测定血浆中普芦卡必利浓度的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0664805A1 (en) 1992-10-13 1995-08-02 Smithkline Beecham Plc Heterocyclic -esters or -amides used as 5-ht 4? receptor antagonists
US5705498A (en) 1992-11-05 1998-01-06 Smithkline Beecham Plc. Piperidine derivatives as 5-HT4 receptor antagonists
FR2756564B1 (fr) * 1996-12-04 2004-05-14 Synthelabo Derives d'acide quinoleine-8-carboxylique, leur preparation et leur application en therapeutique
WO2001095903A1 (en) * 2000-06-15 2001-12-20 Respiratorius Ab 5-ht3 receptor antagonists for treatment of disorders involving airway constriction
KR20060022702A (ko) * 2003-06-19 2006-03-10 얀센 파마슈티카 엔.브이. 5ht4-길항성 4-(아미노메틸)-피페리딘벤즈아미드
DE602004026095D1 (de) 2003-11-24 2010-04-29 Pfizer Chinoloncarbonsäureverbindungen mit 5-ht4-rezeptoragonistischer wirkung
DE602004025508D1 (de) * 2003-12-23 2010-03-25 Serodus As Modulatoren von peripheren 5-ht-rezeptoren
WO2005092882A1 (en) * 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
WO2006090224A1 (en) 2005-02-25 2006-08-31 Pfizer Japan Inc. Benzisoxazole derivatives
JP5075818B2 (ja) 2005-07-22 2012-11-21 ファイザー株式会社 5ht4受容体アゴニストとしてのインダゾールカルボキサミド誘導体
GB0525661D0 (en) * 2005-12-16 2006-01-25 Glaxo Group Ltd Novel compounds
EP2533780B1 (en) 2010-02-12 2017-08-23 AskAt Inc. 5-ht4 receptor agonists for the treatment of dementia
AU2011216950A1 (en) 2010-02-16 2012-08-23 Pfizer Inc. (R)-4-((4-((4-(tetrahydrofuran-3-yloxy) benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol, a partial agonist of 5-HT4 receptors

Also Published As

Publication number Publication date
EP2976337B1 (en) 2018-05-02
US20160280694A1 (en) 2016-09-29
ZA201506804B (en) 2016-07-27
HK1217483A1 (zh) 2017-01-13
AP2015008742A0 (en) 2015-09-30
WO2014147636A1 (en) 2014-09-25
MX364929B (es) 2019-05-14
EA029365B1 (ru) 2018-03-30
CA2907620A1 (en) 2014-09-25
US9790211B2 (en) 2017-10-17
IN2013CH01199A (OSRAM) 2015-08-14
AU2013382944A1 (en) 2015-10-08
AU2013382944B2 (en) 2016-08-04
NZ712369A (en) 2016-11-25
CN105164119A (zh) 2015-12-16
MX2015012350A (es) 2016-05-09
CA2907620C (en) 2018-03-13
ES2674993T3 (es) 2018-07-05
JP6185650B2 (ja) 2017-08-23
EP2976337A1 (en) 2016-01-27
EA201591844A1 (ru) 2016-08-31
JP2016516089A (ja) 2016-06-02
KR101815307B1 (ko) 2018-01-04
SG11201507763RA (en) 2015-10-29
BR112015024060A2 (pt) 2017-07-18
KR20160004274A (ko) 2016-01-12
WO2014147636A8 (en) 2014-12-04
CN105164119B (zh) 2017-12-08

Similar Documents

Publication Publication Date Title
AU2016217461B2 (en) Amide compounds as 5-HT4 receptor agonists
DK2507225T3 (en) L-DIHYDRO-2-OXOQUINOLIN COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS
DK3099675T3 (en) INDAZOLIC COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS
AU2013382944B2 (en) 5-Amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists
HK1217483B (en) 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
HK1241363A1 (en) Amide compounds as 5-ht4 receptor agonists
HK1241363B (zh) 作为5-ht4受体激动剂的酰胺化合物